Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Image-guided breast biopsy and marker/localization placement. Main billing specialties: radiology and general surgery.
Medicare fee-for-service breast biopsy & localization cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 337 | 21,034+1.6%/yr | +1.6%/yr | 6.70.9× | 42% | 26,600 in 2030+4%/yr |
| New York | 288 | 16,847+0.4%/yr | +0.4%/yr | 9.91.4× | 43% | 18,000 in 2030+1.1%/yr |
| Florida | 245 | 16,085−0.7%/yr | −0.7%/yr | 7.71.1× | 39% | 18,600 in 2030+2.5%/yr |
| Texas | 203 | 11,818−2.4%/yr | −2.4%/yr | 5.90.8× | 24% | 13,700 in 2030+2.5%/yr |
| Pennsylvania | 180 | 9,684−1.2%/yr | −1.2%/yr | 7.61.1× | 8% | 10,100 in 2030+0.8%/yr |
| Illinois | 165 | 9,253−2.3%/yr | −2.3%/yr | 7.11.0× | 8% | 9,520 in 2030+0.5%/yr |
| North Carolina | 133 | 8,308−3%/yr | −3%/yr | 9.01.3× | 45% | 8,490 in 2030+0.4%/yr |
| Virginia | 130 | 7,399−0.8%/yr | −0.8%/yr | 7.41.0× | 20% | 9,210 in 2030+3.7%/yr |
| Massachusetts | 117 | 7,183−0.3%/yr | −0.3%/yr | 8.01.1× | 12% | 8,190 in 2030+2.2%/yr |
| Ohio | 133 | 7,179−2.5%/yr | −2.5%/yr | 7.01.0× | 2% | 6,960 in 2030−0.5%/yr |
| New Jersey | 124 | 7,0630%/yr | 0%/yr | 7.11.0× | 39% | 8,480 in 2030+3.1%/yr |
| Georgia | 103 | 5,906−2.9%/yr | −2.9%/yr | 7.31.0× | 17% | 6,640 in 2030+2%/yr |
| Michigan | 102 | 5,736−6.4%/yr | −6.4%/yr | 7.31.0× | 5% | 5,320 in 2030−1.2%/yr |
| Washington | 88 | 5,486−3%/yr | −3%/yr | 7.61.1× | 47% | 5,580 in 2030+0.3%/yr |
| Missouri | 83 | 5,112−2.1%/yr | −2.1%/yr | 8.81.2× | 2% | 5,760 in 2030+2%/yr |
| Maryland | 79 | 5,089−2.2%/yr | −2.2%/yr | 6.00.8× | 73% | 5,630 in 2030+1.7%/yr |
| Indiana | 62 | 4,663−4%/yr | −4%/yr | 7.01.0× | 15% | 4,600 in 2030−0.2%/yr |
| Arizona | 73 | 4,473−1.9%/yr | −1.9%/yr | 6.40.9× | 70% | 4,560 in 2030+0.3%/yr |
| Tennessee | 81 | 4,468−4.7%/yr | −4.7%/yr | 6.81.0× | 31% | 4,740 in 2030+1%/yr |
| South Carolina | 68 | 3,858−2.4%/yr | −2.4%/yr | 6.00.8× | 11% | 4,310 in 2030+1.8%/yr |
| Wisconsin | 59 | 3,773−5.8%/yr | −5.8%/yr | 7.21.0× | 14% | 4,380 in 2030+2.5%/yr |
| Minnesota | 64 | 3,656−3.2%/yr | −3.2%/yr | 8.71.2× | 38% | 4,430 in 2030+3.2%/yr |
| Colorado | 51 | 3,013−3.3%/yr | −3.3%/yr | 6.60.9× | 36% | 3,380 in 2030+1.9%/yr |
| Kentucky | 49 | 3,005−2.2%/yr | −2.2%/yr | 7.01.0× | 6% | 3,430 in 2030+2.2%/yr |
| Connecticut | 40 | 2,686−4.5%/yr | −4.5%/yr | 8.71.2× | 23% | 2,760 in 2030+0.5%/yr |
| Louisiana | 36 | 2,413−3.9%/yr | −3.9%/yr | 6.30.9× | 14% | 2,390 in 2030−0.2%/yr |
| Oklahoma | 56 | 2,408+1%/yr | +1%/yr | 5.20.7× | 2% | 2,580 in 2030+1.1%/yr |
| Oregon | 39 | 2,381−1.7%/yr | −1.7%/yr | 6.10.9× | 34% | 2,430 in 2030+0.3%/yr |
| Alabama | 36 | 2,322−3.8%/yr | −3.8%/yr | 5.70.8× | 10% | 2,460 in 2030+1%/yr |
| Arkansas | 39 | 2,201−3.4%/yr | −3.4%/yr | 6.20.9× | 36% | 2,190 in 2030−0.1%/yr |
| Iowa | 33 | 2,153−2.2%/yr | −2.2%/yr | 5.10.7× | 38% | 2,780 in 2030+4.4%/yr |
| Kansas | 31 | 2,002−2.5%/yr | −2.5%/yr | 5.20.7× | 34% | 2,170 in 2030+1.4%/yr |
| Nebraska | 32 | 1,959−0.6%/yr | −0.6%/yr | 7.91.1× | 31% | 2,180 in 2030+1.8%/yr |
| District of Columbia | 28 | 1,896+2.5%/yr | +2.5%/yr | 31.64.4× | 69% | 2,250 in 2030+2.9%/yr |
| Mississippi | 36 | 1,779−6.5%/yr | −6.5%/yr | 5.00.7× | 22% | 1,620 in 2030−1.5%/yr |
| Rhode Island | 25 | 1,437+8.2%/yr | +8.2%/yr | 17.12.4× | 37% | 1,840 in 2030+4.2%/yr |
| New Hampshire | 20 | 1,151−0.9%/yr | −0.9%/yr | 5.30.7× | 19% | 1,410 in 2030+3.4%/yr |
| Nevada | 22 | 1,149−6.4%/yr | −6.4%/yr | 4.30.6× | 53% | 1,270 in 2030+1.7%/yr |
| New Mexico | 18 | 1,102−4.4%/yr | −4.4%/yr | 5.10.7× | 61% | 1,100 in 20300%/yr |
| Delaware | 19 | 1,063−4.7%/yr | −4.7%/yr | 6.50.9× | 26% | 1,140 in 2030+1.1%/yr |
| Utah | 20 | 1,028−3.6%/yr | −3.6%/yr | 5.00.7× | 9% | 990 in 2030−0.7%/yr |
| West Virginia | 16 | 949−6.7%/yr | −6.7%/yr | 4.90.7× | 8% | 890 in 2030−1%/yr |
| South Dakota | 17 | 929−4.9%/yr | −4.9%/yr | 7.51.1× | 23% | 1,270 in 2030+5.3%/yr |
| Maine | 16 | 918−3.4%/yr | −3.4%/yr | 6.30.9× | 0% | 1,010 in 2030+1.6%/yr |
| Idaho | 12 | 906−4.7%/yr | −4.7%/yr | 4.70.7× | 5% | 1,220 in 2030+5.1%/yr |
| North Dakota | 20 | 868+4.3%/yr | +4.3%/yr | 9.11.3× | 6% | 1,140 in 2030+4.7%/yr |
| Montana | 12 | 694−8%/yr | −8%/yr | 3.80.5× | 5% | 810 in 2030+2.7%/yr |
| Hawaii | 10 | 618−1.8%/yr | −1.8%/yr | 5.20.7× | 25% | 620 in 2030−0.1%/yr |
| Vermont | 13 | 477−0.9%/yr | −0.9%/yr | 4.40.6× | 0% | 1,320 in 2030+18%/yr |
| Alaska | 5 | 464+1.2%/yr | +1.2%/yr | 3.90.5× | 27% | 500 in 2030+1.3%/yr |
| Wyoming | 7 | 456+3.2%/yr | +3.2%/yr | 4.30.6× | 50% | 540 in 2030+2.9%/yr |
Professional codes (what the surgeon bills): CPT 19081, 19083, 19085, 19281, 19283, 19285.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 46 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 22 companies. The most active:
Product codes: NEU (marker, radiographic, implantable), PDW (internal tissue marker), POY (post breast biopsy hemostatic breast compression device), PXP (breast biopsy / localization tray). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +2 pts since 2019, to 29%.
The 10 busiest do 12% of the cases CMS names in California; 181 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Tumor & fibroid embolization | 314 | 18,000+6%/yr | +6%/yr | 42,100 in 2030+15%/yr |
| Tumor ablation | 63 | 8,642+0.4%/yr | +0.4%/yr | 12,000 in 2030+5.6%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 28 companies reported engagement with surgeons in the covered states worth $11M in consulting, speaking, meals and travel tied to these products, about $2,974 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.